SEC Comment Letter for Cyclerion Therapeutics, Inc. (CYCN) (CIK 0001755237) (KRSA) — Dec 28, 2023
Cyclerion Therapeutics, Inc. (CYCN) (CIK 0001755237)
Date: Dec. 28, 2023 · CIK: 0001755237 · Accession: 0000000000-23-014145
AI Filing Summary & Sentiment
File numbers found in text: 001-38787
Letter
United States securities and exchange commission logo December 28, 2023 Peter M. Hecht Chief Executive Officer Cyclerion Therapeutics, Inc. 245 First Street, 18 Floor Cambridge , Massachusetts Re:Cyclerion Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 22, 2023 File No. 001-38787 Dear Peter M. Hecht: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
December 28, 2023
Peter M. Hecht
Chief Executive Officer
Cyclerion Therapeutics, Inc.
245 First Street, 18 Floor
Cambridge , Massachusetts
Re:Cyclerion Therapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed March 22, 2023
File No. 001-38787
Dear Peter M. Hecht:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences